Our Laboratory Head Kirsten joined Anaveon in June 2021, from Roche pRED where she led preclinical drug discovery projects using locked nucleic acids, small or large molecules to modulate the immune response in the fields of antibiotics, virology, and autoimmunity. Before that, Kirsten was Oberassistentin/senior scientist at the Swiss Federal Institute of Technology (ETH) in Zurich focusing on the immune response in chronic viral infection. She obtained her PhD in Freiburg, Germany. Kirsten has broad immunology expertise and especially likes T cells.
- Anaveon presents clinical trial OMNIA-2 at the American Society of Clinical Oncology 2023 Annual MeetingJune 5, 2023
- Anaveon Presents Trial in Progress Data for OMNIA-1 at the American Society of Clinical Oncology 2023 Annual MeetingJune 3, 2023
- Anaveon presents ANV600, a novel development compound, at the 2023 American Association for Cancer Research Annual MeetingApril 18, 2023